For comprehensive information about Parkinson’s diagnosis please visit the EPDA website.
European Union announces new programme to improve Parkinson’s diagnosis
Author: Parkinson's Life editorsPublished: 17 January 2018
Prep: Cook: Serves:
The European Union has announced the launch of the Magnetic Diagnostic Assay for Neurodegenerative Diseases (MADIA) – a project with the ultimate goal of improving diagnosis for those living with Parkinson’s and Alzheimer’s.
The project, which is in partnership with a range of international universities and institutions, will focus on the development of a novel device that will help clinicians perform a simple click and analysis to diagnose both conditions.
Dr Francisco Campos, of the Clinical Neurosciences Research Laboratory, said: “An early diagnosis is crucial to maximise the effectiveness of the treatments in order to mitigate the devastating effects of these illnesses and slow disease progression.
“MADIA is funded by the European Union’s Horizon 2020 research and innovation programme, and consists of a multitasking team with more than 50 professionals in the fields of biology, physics and engineering.”
Share this story
Telemedicine: how Sweden is reducing waiting times for Parkinson’s treatment
Video calling tech is speeding up access to advanced treatmentREAD MORE
Online video campaign ‘gives life’ to powerful Parkinson’s stories
Campaign calling for inspiring video testimonials from patientsREAD MORE
A better way to assess the impact of Parkinson’s
EPDA experts launch pilot 'quality of life' studyREAD MORE